QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Takes Part in Groundbreaking Genomes Project
Predictive Oncology (NASDAQ: POAI) is a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments. An article discussing the company reads, “As part of Predictive Oncology’s commitment to determining the best pathways for more individualized and effective cancer treatment, one of its main subsidiaries – Helomics – partnered with the UK 100,000 Genomes Project (‘UK100K’) in a research study focused on driving precision medicine to help conquer ovarian cancer. The UK100K initiative couples whole-genome sequencing of National Health Service (NHS) patients with cancer and other diseases to rich clinical data on drug treatments and outcomes.…